These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33627051)

  • 21. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
    Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet; 2021 Sep; 398(10303):856-869. PubMed ID: 34370971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 vaccines for cancer patients: a call to action.
    Corti C; Crimini E; Tarantino P; Pravettoni G; Eggermont AMM; Delaloge S; Curigliano G
    Eur J Cancer; 2021 May; 148():316-327. PubMed ID: 33770576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric COVID-19 Health Disparities and Vaccine Equity.
    Oliveira CR; Feemster KA; Ulloa ER
    J Pediatric Infect Dis Soc; 2022 Dec; 11(Supplement_4):S141-S147. PubMed ID: 36124679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
    Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study.
    Agrawal U; Katikireddi SV; McCowan C; Mulholland RH; Azcoaga-Lorenzo A; Amele S; Fagbamigbe AF; Vasileiou E; Grange Z; Shi T; Kerr S; Moore E; Murray JLK; Shah SA; Ritchie L; O'Reilly D; Stock SJ; Beggs J; Chuter A; Torabi F; Akbari A; Bedston S; McMenamin J; Wood R; Tang RSM; de Lusignan S; Hobbs FDR; Woolhouse M; Simpson CR; Robertson C; Sheikh A
    Lancet Respir Med; 2021 Dec; 9(12):1439-1449. PubMed ID: 34599903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The UPTAKE study: a cross-sectional survey examining the insights and beliefs of the UK population on COVID-19 vaccine uptake and hesitancy.
    Sethi S; Kumar A; Mandal A; Shaikh M; Hall CA; Kirk JMW; Moss P; Brookes MJ; Basu S
    BMJ Open; 2021 Jun; 11(6):e048856. PubMed ID: 34130964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Racial/Ethnic Differences in COVID-19 Vaccine Hesitancy Among Health Care Workers in 2 Large Academic Hospitals.
    Momplaisir FM; Kuter BJ; Ghadimi F; Browne S; Nkwihoreze H; Feemster KA; Frank I; Faig W; Shen AK; Offit PA; Green-McKenzie J
    JAMA Netw Open; 2021 Aug; 4(8):e2121931. PubMed ID: 34459907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 2020 race towards SARS-CoV-2 specific vaccines.
    Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D
    Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigating the association between ethnicity and health outcomes in SARS-CoV-2 in a London secondary care population.
    Patel A; Abdulaal A; Ariyanayagam D; Killington K; Denny SJ; Mughal N; Hughes S; Goel N; Davies GW; Moore LSP; Charani E
    PLoS One; 2020; 15(10):e0240960. PubMed ID: 33112892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
    Emary KRW; Golubchik T; Aley PK; Ariani CV; Angus B; Bibi S; Blane B; Bonsall D; Cicconi P; Charlton S; Clutterbuck EA; Collins AM; Cox T; Darton TC; Dold C; Douglas AD; Duncan CJA; Ewer KJ; Flaxman AL; Faust SN; Ferreira DM; Feng S; Finn A; Folegatti PM; Fuskova M; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hallis B; Heath PT; Hay J; Hill HC; Jenkin D; Kerridge S; Lazarus R; Libri V; Lillie PJ; Ludden C; Marchevsky NG; Minassian AM; McGregor AC; Mujadidi YF; Phillips DJ; Plested E; Pollock KM; Robinson H; Smith A; Song R; Snape MD; Sutherland RK; Thomson EC; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Williams CJ; Hill AVS; Lambe T; Gilbert SC; Voysey M; Ramasamy MN; Pollard AJ; ; ;
    Lancet; 2021 Apr; 397(10282):1351-1362. PubMed ID: 33798499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primed for global coronavirus pandemic: Emerging research and clinical outcome.
    Ahamad S; Branch S; Harrelson S; Hussain MK; Saquib M; Khan S
    Eur J Med Chem; 2021 Jan; 209():112862. PubMed ID: 33070079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
    Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
    BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disparities in national and state estimates of COVID-19 vaccination receipt and intent to vaccinate by race/ethnicity, income, and age group among adults ≥ 18 years, United States.
    Nguyen KH; Anneser E; Toppo A; Allen JD; Scott Parott J; Corlin L
    Vaccine; 2022 Jan; 40(1):107-113. PubMed ID: 34852946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessing barriers to access and equity for COVID-19 vaccination in the US.
    Kuehn M; LaMori J; DeMartino JK; Mesa-Frias M; Doran J; Korrapati L; Bhojwani R; Lefebvre P; Kirson N
    BMC Public Health; 2022 Dec; 22(1):2263. PubMed ID: 36463172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
    Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
    Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors Associated With Racial/Ethnic Group-Based Medical Mistrust and Perspectives on COVID-19 Vaccine Trial Participation and Vaccine Uptake in the US.
    Thompson HS; Manning M; Mitchell J; Kim S; Harper FWK; Cresswell S; Johns K; Pal S; Dowe B; Tariq M; Sayed N; Saigh LM; Rutledge L; Lipscomb C; Lilly JY; Gustine H; Sanders A; Landry M; Marks B
    JAMA Netw Open; 2021 May; 4(5):e2111629. PubMed ID: 34042990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethnic differences in COVID-19 mortality in the second and third waves of the pandemic in England during the vaccine rollout: a retrospective, population-based cohort study.
    Bosworth ML; Ahmed T; Larsen T; Lorenzi L; Morgan J; Ali R; Goldblatt P; Islam N; Khunti K; Raleigh V; Ayoubkhani D; Bannister N; Glickman M; Nafilyan V
    BMC Med; 2023 Jan; 21(1):13. PubMed ID: 36617562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
    Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.